Taken together, it is concluded in the current study that HDAC inhibitor ITF2357 downregulates HDAC2, and thus increases the expression of miR-130a-3p and decreases the expression of Rad51, diminishing the resistance of mut-KRAS NSCLC to Pem (Fig. 8). This evidence concerns the gene KRAS and non-small cell lung carcinoma.